Type 2 diabetes mellitus. Type 2 diabetes mellitus
Conditions
Interventions
Intervention 1: Intervention group: Patients in this group consume one 500 mg capsule of the herbal combination every 12 hours after meal for 3 months. The capsule contains mixture of the extracts of
Sponsors
Iranian academic center for education culture and research
Eligibility
Sex/Gender
All
Age
40 Years to 60 Years
Inclusion criteria
Inclusion criteria: Non-insulin-dependent type 2 diabetic patients with mild to moderate severity of disease Patients not needing insulin for at least two years Patients under treatment with oral blood glucose lowering drugs or diet Fasting blood glucose level between 130 to 160 mg/dL with drugs or diet Fasting levels of glucose between 130 and 160 mg/dL and HbA1c between 7 and 8.5 percent at least 2 months before start of study Signature of the project informed consent form
Exclusion criteria
Exclusion criteria: Patients with diabetic foot ulcer Patients with gangrene Patients with serious disease like renal failure, chronic liver failure, uncompensated heart failure, pulmonary infection, and proliferative retinopathy Patients with painful diabetic neuropathy Patients with active neoplastic disease Patients with a history of less than 5 years of cancer Patients with depression Smokers Alcoholic patients Patients inclined to change exercise program or diet
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Glycosylated hemoglobin blood level. Timepoint: At the start of study and 3 months after intervention. Method of measurement: Glycosylated hemoglobin blood level will be determined in laboratory by standard kit.;Fasting blood glucose level. Timepoint: At the start of study and 3 months after intervention. Method of measurement: Fasting blood glucose level will be determined in laboratory standard kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood triglyceride level. Timepoint: At the start of study and 3 months after intervention. Method of measurement: Blood triglyceride level will be determined in laboratory by standard kit.;Total cholesterol blood level. Timepoint: At the start of study and 3 months after intervention. Method of measurement: Total cholesterol blood level will be determined in laboratory by standard kit.;Low-density lipoprotein cholesterol blood level. Timepoint: At the start of study and 3 months after intervention. Method of measurement: Low-density lipoprotein cholesterol blood level will be determined in laboratory by standard kit.;High-density lipoprotein cholesterol blood level. Timepoint: At the start of study and 3 months after intervention. Method of measurement: High-density lipoprotein cholesterol blood level will be determined in laboratory by standard kit.;Aspartate aminotransferase blood level. Timepoint: At the start of study and after 3 months of intervention. Method of measurement: Aspartate aminotransferase blood level will be determined in laboratory by standard kit.;Alanine aminotransferase blood level. Timepoint: At the start of study and 3 months after intervention. Method of measurement: Alanine aminotransferase blood level will be determined in laboratory by standard kit.;Level of blood urea nitrogen. Timepoint: At the start of study and 3 months after intervention. Method of measurement: Level of blood urea nitrogen will be determined in laboratory by standard kit.;Blood creatinine level. Timepoint: At the start of study and 3 months after intervention. Method of measurement: Blood creatinine level will be determined in laboratory by standard kit.;Complete blood count. Timepoint: At the start of study and 3 months after intervention. Method of measurement: Complete blood count will be performed in laboratory by auto-analyzer. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSaeed Kianbakht
Iranian academic center for education culture and research
Outcome results
None listed